Skip to main content
Grant Details

Grant Number: 4R37CA214785-06 Interpret this number
Primary Investigator: Blinder, Victoria
Organization: Sloan-Kettering Inst Can Research
Project Title: The Breast Cancer and the Workforce Communication App: a Randomized Controlled Trial of an English/Spanish Intervention to Promote Long-Term Job Retention
Fiscal Year: 2023


Abstract

ABSTRACT Job loss is one of the most impactful, yet understudied, stressors associated with a breast cancer diagnosis. Long-term financial consequences can include difficulty paying bills, accumulation of debt, and bankruptcy. Importantly, bankruptcy in cancer survivors has been linked to increased mortality. Women with access to work accommodations, such as schedule flexibility, are more likely to work during chemotherapy and to retain their jobs in the long term. Similarly, women with adequate sick leave may choose to take time off while maintaining job security. However, low-income minorities are less likely to have such accommodations, leading to higher rates of job loss and financial distress. For these patients, finding a way to continue to work during treatment is critical. In the Breast Cancer and the Workforce study, which focuses on immigrant and minority women, only 57% of pre-diagnosis employed low-income women retained their jobs after treatment completion, compared to 93% of higher-income women. Low-income women were less than half as likely as higher-income women to have accommodating employers and only one-fourth as likely to retain their jobs. However, patients whose confidence in asking for work accommodations improved over time were more than five times as likely to retain their jobs than those whose confidence did not improve. Based on these data, we developed the Breast Cancer and the Workforce Communication App. The goal of the parent study is to evaluate the effectiveness of this app in promoting job retention among women undergoing adjuvant (curative) breast cancer chemotherapy. For the proposed extension, we will build on the funded study by extending the follow-up of participants to 3 years, providing a long-term view of work in the post-treatment survivorship period. Additionally, we will evaluate the effect of our app on overall financial hardship in the long term, providing critical knowledge that will enhance our understanding of the relationship between work and financial hardship and of the role that interventions focused on work (such as ours) may have in attenuating financial hardship. The proposed extension has two main components that will allow us to study long-term work outcomes and better understand the effect of decreased wages and job loss on long-term financial hardship. In Aim 1, we will extend post- treatment follow-up to 3 years to 1) gain a longer-term perspective of work outcomes in breast cancer survivors, 2) evaluate changes in access to accommodations over time, and 3) evaluate work outcomes based on receipt of extended post-operative chemotherapy (which has become the standard of care for some patients in the time since the parent study was funded). In Aim 2, we will measure the relationship between work and financial hardship by correlating patient-reported changes in employment (work status, work hours, and earnings) to subjective and objective indicators of financial hardship. Additionally, we will conduct semi- structured interviews with a subset of study participants to identify pathways leading to financial hardship and to better understand the relationship between work and financial hardship.



Publications

An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial.
Authors: Blinder V.S. , Patil S. , Finik J. , Makower D. , Muppidi M. , Lichtenthal W.G. , Parker P.A. , Claros M. , Suarez J. , Narang B. , et al. .
Source: Trials, 2022-10-03; 23(1), p. 840.
EPub date: 2022-10-03.
PMID: 36192754
Related Citations

Effects of patient-reported outcome assessment order.
Authors: Novotny P.J. , Dueck A.C. , Satele D. , Frost M.H. , Beebe T.J. , Yost K.J. , Lee M.K. , Eton D.T. , Yount S. , Cella D. , et al. .
Source: Clinical trials (London, England), 2022 Jun; 19(3), p. 307-315.
EPub date: 2022-01-28.
PMID: 35088616
Related Citations

Work Status Reduction and Cost-Related Nonadherence during Cancer Treatment.
Authors: Doherty M. , Finik J. , Blinder V. .
Source: Health & social work, 2022-04-13; 47(2), p. 123-130.
PMID: 35253845
Related Citations

Vulnerabilities in workplace features for essential workers with breast cancer: Implications for the COVID-19 pandemic.
Authors: Klugman M. , Patil S. , Gany F. , Blinder V. .
Source: Work (Reading, Mass.), 2022; 71(4), p. 815-823.
PMID: 35253716
Related Citations

Pain, Financial Hardship, and Employment in Cancer Survivors.
Authors: Blinder V.S. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022-01-01; 40(1), p. 1-4.
EPub date: 2021-11-18.
PMID: 34793249
Related Citations

The association between housing and food insecurity among medically underserved cancer patients.
Authors: Gany F. , Melnic I. , Ramirez J. , Wu M. , Li Y. , Paolantonio L. , Roberts-Eversley N. , Blinder V. , Leng J. .
Source: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021 Dec; 29(12), p. 7765-7774.
EPub date: 2021-06-24.
PMID: 34169329
Related Citations

Use of patient-reported controls for secular trends to study disparities in cancer-related job loss.
Authors: Blinder V.S. , Eberle C.E. , Tran C. , Bao T. , Malik M. , Jung G. , Hwang C. , Kampel L. , Patil S. , Gany F.M. .
Source: Journal of cancer survivorship : research and practice, 2021 Oct; 15(5), p. 685-695.
EPub date: 2020-10-26.
PMID: 33106995
Related Citations

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
Authors: Tolaney S.M. , Garrett-Mayer E. , White J. , Blinder V.S. , Foster J.C. , Amiri-Kordestani L. , Hwang E.S. , Bliss J.M. , Rakovitch E. , Perlmutter J. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021-08-20; 39(24), p. 2720-2731.
EPub date: 2021-05-18.
PMID: 34003702
Related Citations

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic.
Authors: Park K.U. , Gregory M. , Bazan J. , Lustberg M. , Rosenberg S. , Blinder V. , Sharma P. , Pusztai L. , Shen C. , Partridge A. , et al. .
Source: Breast cancer research and treatment, 2021 Jul; 188(1), p. 249-258.
EPub date: 2021-03-02.
PMID: 33651271
Related Citations

Breast Cancer-Related Employment Disruption and Financial Hardship in the Sister Study.
Authors: Meernik C. , Sandler D.P. , Peipins L.A. , Hodgson M.E. , Blinder V.S. , Wheeler S.B. , Nichols H.B. .
Source: JNCI cancer spectrum, 2021 Jun; 5(3), .
EPub date: 2021-03-17.
PMID: 34104865
Related Citations

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Authors: Autio K.A. , Klebanoff C.A. , Schaer D. , Kauh J.S.W. , Slovin S.F. , Adamow M. , Blinder V.S. , Brahmachary M. , Carlsen M. , Comen E. , et al. .
Source: Clinical cancer research : an official journal of the American Association for Cancer Research, 2020-11-01; 26(21), p. 5609-5620.
EPub date: 2020-08-26.
PMID: 32847933
Related Citations

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Authors: Wang D.G. , Barrios D.M. , Blinder V.S. , Bromberg J.F. , Drullinsky P.R. , Funt S.A. , Jhaveri K.L. , Lake D.E. , Lyons T. , Modi S. , et al. .
Source: Breast cancer research and treatment, 2020 Aug; 183(1), p. 227-237.
EPub date: 2020-06-29.
PMID: 32613539
Related Citations

Impact of Cancer on Employment.
Authors: Blinder V.S. , Gany F.M. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020-02-01; 38(4), p. 302-309.
EPub date: 2019-12-05.
PMID: 31804857
Related Citations




Back to Top